Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM326 (Stapokibart) in Adult Atopic Dermatitis
NCT05671445Phase 2Unknown
- Sponsor
- Keymed Biosciences
- Start
- Feb 2023
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of stapokibart in atopic dermatitis (AD), sponsored by Keymed Biosciences. Status: unknown.
02
Drugs
stapokibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05671445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05671445.